ConjuChem

ConjuChem Biotechnologies Inc.

Company type	Public (TSX has Delisted this Stock)
Industry	Biotechnology
Headquarters	Montreal, Quebec , Canada
Key people	Mark Perrin
Products	Drug Affinity Construct (DAC) and Preformed Conjugate-Drug Affinity Construct (PC-DAC)
Number of employees	44^[citation needed]^[needs update]
Website	www.conjuchem.com

ConjuChem Biotechnologies Inc. is a medical biotechnology company located in Montreal, Quebec, Canada^[1] which is credited with inventing the experimental peptide hormone CJC-1295.^[2][3]

It employs 45 people, 90% of whom are in research and development.^{[citation needed][needs update]}

References

1. "Conjuchem Biotechnologies Inc". Bloomberg Business. Retrieved 18 June 2015.
2. Teichman, Sam L.; Neale, Ann; Lawrence, Betty; Gagnon, Catherine; Castaigne, Jean-Paul; Frohman, Lawrence A. (2006). "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults". The Journal of Clinical Endocrinology & Metabolism. 91 (3): 799–805. doi:10.1210/jc.2005-1536. ISSN 0021-972X. PMID 16352683.
3. "CJC-1295 or Modified GRF (1-29)". American Science Labs. 9 February 2015. Archived from the original on 18 June 2015. Retrieved 18 June 2015.

External links

• Official website